Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA for Adductor Spasmodic Dysphonia
NCT05158166Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in adductor spasmodic dysphonia (ADSD), sponsored by University of California, San Francisco. Started Oct 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
adductor spasmodic dysphonia (ADSD)
Beyond the preview
Go deeper on NCT05158166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158166.